EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Current approaches to the development of vaccines effective against parainfluenza viruses



Current approaches to the development of vaccines effective against parainfluenza viruses



Bulletin of the World Health Organization 66(3): 391-397



The author summarizes the proceedings of a joint workshop of the WHO and the National Institutes of Health in Bethesda in 1987 on new vaccine development. Attention was focused on parainfluenza (perhaps as something of a relief from the frustrations of influenza and respiratory syncytial virus (RSV)). Parainfluenzas 1 and 2 are notable causes of croup, and parainfluenza 3 (PIV3) of croup and bronchiolitis. As a respiratory-tract pathogen in young children PIV3 is second only to RSV.

(PDF emailed within 1 workday: $29.90)

Accession: 001790454

Download citation: RISBibTeXText

PMID: 2844427



Related references

Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Research 11(1): 1-15, 1988

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine 13(4): 415-421, 1995

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus and parainfluenza virus A meeting report of the WHO Programme for Vaccine Development. Vaccine 13(4): 415-421, 1995

An update on approaches to the development of respiratory syncytial virus and parainfluenza virus type 3 vaccines. Virus Research 32(1): 13-36, 1994

An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research 32(1): 13-36, 1994

Challenges of influenza A viruses in humans and animals and current animal vaccines as an effective control measure. Clinical and Experimental Vaccine Research 7(1): 1-15, 2018

Development of effective subunit vaccines against enveloped viruses. Progress in Clinical and Biological Research 47: 217-228, 1980

Effects of bovine viral diarrhea and parainfluenza-3 virus vaccines on development of respiratory tract diarrhea and parainfluenza-3 virus vaccines on development of respiratory tract disease in calves. Journal of the American Veterinary Medical Association: 163 (7 pt 1) 742-744, 1973

Current situation of the development of vaccines against respiratory viruses. Revista Argentina de Tuberculosis Enfermedades Pulmonares y Salud Publica 48(1): 35-38, 1987

Prevention of tuberculosis: current approaches to development of vaccines. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk: 45-52, 2013

Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer. Journal of Breast Cancer 21(4): 343-353, 2019

The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines. Expert Review of Vaccines 2019, 2019

Using combinatorial bioinformatics methods to analyze annual perspective changes of influenza viruses and to accelerate development of effective vaccines. Journal of the Formosan Medical Association 114(8): 774-778, 2016

Current concepts and future approaches to the development of autologous/autogenous vaccines for veterinary use. Developments in Biologicals 117: 55-60, 2004

Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. Journal of Clinical Investigation 110(1): 21-27, 2002